Alembic Pharmaceuticals Ltd reported a significant 29% increase in consolidated net profit for the fourth quarter of FY26, reaching ₹202.7 crore compared to ₹156.89 crore in the same period last year. The company's consolidated revenue from operations also saw a rise, totaling ₹1,847.72 crore, up from ₹1,769.64 crore in Q4 FY25. This growth is attributed to effective execution across various business segments and a strategic focus on profitability, as highlighted by Managing Director Pranav Amin. He noted that the company maintained healthy pre-research and development operating margins while expanding its market presence. Notably, Alembic entered the branded business in the United States with the launch of its product Pivya, which is expected to contribute to long-term growth. For the entire fiscal year 2026, Alembic Pharmaceuticals reported a consolidated net profit of ₹6,638.61 crore, an increase from ₹6,021.19 crore in FY25, with total revenue from operations reaching ₹7,344.9 crore, compared to ₹6,672.08 crore the previous year. Additionally, the board has proposed a dividend of ₹12 per share for shareholders.